Table 1 Characteristics of life-threatening complications observed in blinatumomab-treated patients

Patients with life-threatening event

10

Blinatumomab cycle

 1st cycle

6 (60)

 2nd cycle

2 (20)

 3rd or > cycle

2 (20)

Inpatient monitoring for first days’ administration

10 (100)

Pre-blinatumomab status

 CR MRD neg

4 (40)

 CR MRD pos

4 (40)

 Not CR

2 (20)

Blinatumomab schedule

 9—28 mcg/day

4 (40)

 28 mcg/day

6 (60)

Toxicity cause

 CRS

3 (30)

 ICANS

3 (30)

 CRS and ICANS

1 (10)

 Clinical sepsis

3 (30)

Documented infection

5 (50)

 Clinical

1

 Microbiological

4

Characteristics at ICU admission (n = 8)

 Fever, n° (%)

4 (50)

 Hypotension, n° (%)

5 (62.5)

 Hypoxemia, n° (%)

0 (0)

 SOFA score, median (range)

3.5 (1–6)

 KDIGO, median (range)

0 (0–0)

 GCS, median (range)

15 (6–15)

Interventions

 Dexamethasone

4 (40)

 Tocilizumab

0 (0)

 Antibiotic therapy

9 (90)

 Fluid replacement

6 (60)

 Vasoactive drugs

2 (20)

 Mechanical ventilation

3 (30)

 Renal replacement therapy

0 (0)

Deaths

3 (30)

Death cause

 CRS only

1

 CRS and ICANS

1

 Infection

1